New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareSyn-Coll vs Chonluten

Syn-Coll vs Chonluten

Side-by-side comparison of key properties, dosing, and research.

Skin & CosmeticAnti-Aging & Longevity
Syn-Coll
Anti-Aging & Longevity
Chonluten
Summary
Syn-Coll is a palmitoylated tripeptide (Palmitoyl Tripeptide-5) that mimics thrombospondin-1 to activate TGF-beta, the primary growth factor driving collagen synthesis in the dermis. It is one of the most mechanistically direct collagen-stimulating peptides in cosmetic formulations.
Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
Half-Life
Extended (lipid depot in stratum corneum)
Short (minutes for the peptide); sustained gene-regulatory effects
Admin Route
Topical
SubQ, Oral
Research
Typical Dose
0.005-0.05% in formulation
10 mg per day
Frequency
Once or twice daily
Daily for 10–30 days
Key Benefits
  • Directly activates TGF-beta for potent collagen synthesis stimulation
  • Increases dermal thickness and firmness
  • Reduces depth of wrinkles and fine lines
  • Improves skin elasticity
  • Clinically validated in collagen induction studies
  • Complementary to retinoids or vitamin C
  • Supports bronchial mucosal regeneration and repair
  • May improve mucociliary clearance in chronic respiratory conditions
  • Anti-inflammatory effects on bronchial epithelium
  • Pulmonary anti-aging and tissue preservation
  • Supports lung function in COPD and chronic bronchitis
  • Well tolerated in combination with other Khavinson bioregulators
  • Short tripeptide with efficient cellular penetration
Side Effects
  • Generally well-tolerated
  • Rare mild irritation at high concentrations
  • Possible sensitivity in individuals with inflammatory skin conditions
  • Generally well tolerated
  • Mild injection site reactions possible
  • No significant adverse pulmonary events reported
Stacks With